Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A6 in Chronic Lymphocytic Leukemia
NCT02046928Phase 2Terminated
- Sponsor
- Angstrom Pharmaceuticals
- Start
- Feb 2014
- Primary completion
- Nov 2015
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
A Phase 2 trial of urokinase-derived peptide a6 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Angstrom Pharmaceuticals. Started Feb 2014; status: terminated.
02
Drugs
urokinase-derived peptide a6
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02046928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02046928.